"Our study is the largest of its kind, and our findings suggest that younger women with breast cancer who have a BRCA mutation have similar survival to women who do not carry the mutation after receiving treatment", Eccles said in a press release.
Martin Ledwick, Cancer Research UK's Head Information Nurse, said: "Although BRCA faults increase the risk of young women developing cancer, their outlook once diagnosed is no worse than that for young women with breast cancer who don't carry the BRCA gene faults". About 12 percent of women are diagnosed with breast cancer at some point in their life.
The findings might come as a welcomed breath of fresh air for many young women newly diagnosed with breast cancer, particularly those who are BRCA carriers.More news: Trump weighs-in on Oprah's potential presidential run
"In view of this, younger women with breast cancer can take time to discuss whether radical breast surgery is the right choice for them as part of a longer-term risk reducing strategy", said Fiona MacNeill, a breast surgeon at The Royal Marsden National Health System Foundation Trust in Britain, which was not involved in the study. There was no significant difference in overall survival between patients who were BRCA positive and those who were BRCA negative at 2 years (97% vs 96.6%, respectively), 5 years (83.8% vs 85%), or 10 years (73.4% vs 70.1%; hazard ratio, 0.96; 95% CI, 0.76-1.22; P = 0.76).
"However, our findings suggest that this surgery does not have to be immediately undertaken along with the other treatment".
This is the first time a PARP inhibitor has been approved to treat breast cancer and the first time any drug has been approved to treat certain patients with metastatic breast cancer associated with the same genetic mutation.
"Decisions about timing of additional surgery to reduce future cancer risks should take into account patient prognosis after their first cancer, and their personal preferences", she added.More news: Liverpool, Arsenal must spend £90m to land Thomas Lemar
"It can be hard for some patients to decide whether or not to have risk-reducing surgery, typically double mastectomies and removal of ovaries".
TESARO's PARP inhibitor ZEJULA (niraparib) was OK'd in the U.S.in March 2017 for the maintenance treatment of recurrent epithelial ovarian (and fallopian tube and primary peritoneal cancers) in patients who are in complete or partial response to platinum-based chemo regardless of their BRCA status.
The women, who were recruited between 2000 and 2008, were monitored for an average of 8.2 years to discover more about their treatment, whether their cancer returned, or if they died.More news: Apple releases fifth iOS 11.2.5 beta for iPhone and iPad
She said she was now keen to understand how women fared more than 10 years after their diagnosis. The FDA says it is expanding approval of Lynparza (olaparib) to include use against BRCA-linked tumors that have spread outside the breast.